TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is ga…
Auf dem diesjährigen Kongress der Europäischen Gesellschaft für Kardiologie (ESC) wurden die BIOFLOW-V Studienergebniss…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…
回日本循環器学会学術集会(金沢)のランチョンセミナーにおいて、BIOFLOW-IV国際共同治験の12ヶ月までの結果を発表しました。…
BIOTRONIK, a leading manufacturer of cardio- and endovascular technology, presented 12-month results of the BIOFLOW-IV m…
. Innovatives Medizinprodukt aus sich natürlich abbauendem Material nun auch in den USA erhältlich Funktioniert wie e…
BIOTRONIK today announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Reso…
BIOTRONIK announced today the first patient enrolment in the BIOSTEMI trial. The randomized, controlled superiority tria…
BIOTRONIK, a global leader in cardio- and endovascular medical technology, announced today that enrollment is complete i…